구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 240 trials·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ||
|---|---|---|---|
Overview Program | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | Taxane |
Overview Company | Daiichi Sankyo / AstraZeneca | RemeGen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | Gastric Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High DAR (~8), bystander effect, HER2-low activity | Novel anti-HER2 mAb with distinct epitope | — |
Positioning Known limitation | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | — |
Positioning Development positioning | Leading efficacy in HER2 ADC class | Lower ILD signal vs DXd in some datasets | — |
Technology Payload | DXd (topo-I inhibitor) | MMAE | Deruxtecan in Patients With Previously Treated HER |
Technology Linker | Cleavable tetrapeptide | Cleavable | — |
MoA Mechanism | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | targeting this shared pathway |
MoA Biomarker | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | biomarker-informed trials, rather than to identify a single preferred ICI strategy |
PK/PD Half-life | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ~5 days (ADC, clinical PK) | — |
PK/PD Species | Minipig, Pig, Human, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse, ORR in HER2+ UC/gastric | Mouse, Human |
PK/PD Animal (cat.) | Human, In vitro | Human, Mouse, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic | pd | PD |
PK/PD Biodistribution | Systemic exposure with tumor-selective HER2-mediated uptake | — | — |
Toxicology Species | Cynomolgus monkey, NHP, Rat, Minipig, Pig, Hamster, Human | Cynomolgus monkey, Mouse | Mouse, Human |
Toxicology Animal (cat.) | NHP | NHP | Human, Mouse, In vitro |
Toxicology Major finding | ILD-like lung findings at high exposure | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Toxicology CRS | Minimal | N/A | — |
Toxicology NOAEL | 10 mg/kg | — | — |
Clinical Safety signal | ILD-like lung findings at high exposure | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Selected reported efficacy | ORR 79.7% | — | ORR 36% |
Clinical Reported ORR | 79.7% | — | 36% |
Clinical Reported PFS | NA | — | — |
Clinical Reported OS | NA | — | — |
Clinical Result source | ClinicalTrials.gov NCT03529110 | — | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03529110 | — | NCT00462423 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 240 trials·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ||
|---|---|---|---|
Overview Program | Enhertu (trastuzumab deruxtecan) | Disitamab Vedotin (RC48) | Taxane |
Overview Company | Daiichi Sankyo / AstraZeneca | RemeGen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC | ADC | ADC |
Overview Target | HER2 | HER2 | HER2 |
Overview Indication | HER2+ breast cancer, HER2-low, gastric | HER2+ urothelial, gastric, breast | Gastric Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High DAR (~8), bystander effect, HER2-low activity | Novel anti-HER2 mAb with distinct epitope | — |
Positioning Known limitation | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | resistance mechanisms, optimize payload delivery, and minimize off-target toxicity | — |
Positioning Development positioning | Leading efficacy in HER2 ADC class | Lower ILD signal vs DXd in some datasets | — |
Technology Payload | DXd (topo-I inhibitor) | MMAE | Deruxtecan in Patients With Previously Treated HER |
Technology Linker | Cleavable tetrapeptide | Cleavable | — |
MoA Mechanism | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | Disitamab vedotin binds a distinct HER2 epitope (different from trastuzumab), internalizes, and releases MMAE via cleavable linker, causing microtubule disruption and apoptosis. | targeting this shared pathway |
MoA Biomarker | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | HER2 expression (IHC); activity in HER2+ urothelial and gastric cancers. | biomarker-informed trials, rather than to identify a single preferred ICI strategy |
PK/PD Half-life | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | ~5 days (ADC, clinical PK) | — |
PK/PD Species | Minipig, Pig, Human, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse, ORR in HER2+ UC/gastric | Mouse, Human |
PK/PD Animal (cat.) | Human, In vitro | Human, Mouse, In vitro | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic | pd | PD |
PK/PD Biodistribution | Systemic exposure with tumor-selective HER2-mediated uptake | — | — |
Toxicology Species | Cynomolgus monkey, NHP, Rat, Minipig, Pig, Hamster, Human | Cynomolgus monkey, Mouse | Mouse, Human |
Toxicology Animal (cat.) | NHP | NHP | Human, Mouse, In vitro |
Toxicology Major finding | ILD-like lung findings at high exposure | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Toxicology CRS | Minimal | N/A | — |
Toxicology NOAEL | 10 mg/kg | — | — |
Clinical Safety signal | ILD-like lung findings at high exposure | Hematologic toxicity and peripheral neuropathy class effects of MMAE; ILD reported at lower frequency than DXd ADCs in published datasets. | Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial.. Taxane-induced peripheral neuropathy (TIPN) is a common side effect of chemotherapy that significantly impacts patients' quality of life. This study evaluated the efficacy of professional acupuncture and self-care using press-tack needles for TIPN. In this multicenter randomized controlled trial, 48 patients with… |
Clinical Selected reported efficacy | ORR 79.7% | — | ORR 36% |
Clinical Reported ORR | 79.7% | — | 36% |
Clinical Reported PFS | NA | — | — |
Clinical Reported OS | NA | — | — |
Clinical Result source | ClinicalTrials.gov NCT03529110 | — | ClinicalTrials.gov NCT00462423 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT03529110 | — | NCT00462423 |
Preclinical Animal (cat.) | Human, Mouse, In vitro | — | — |
추천 비교
추천 비교